Fig. 8

High expression of TASL positively correlates with poor clinicopathological features of glioma. A Validation of mRNA expression levels of TASL in cell lines (SVGp12, HS683, U87, and U118) using qRT-PCR. Representative images of IHC staining of TASL in pathological tissues of glioma patients of different WHO grades (40 × and 400x) (B) and statistical plots of TASL protein expression (C). TASL expression in glioma tissues grouped according to different age (D), pathological types (E), IDH1 mutation status (F), positive and negative status of OLIG2 expression (G) and positive rates of Ki-67 expression (H) (*P < 0.05; **P < 0.01; ***P < 0.001)